Recent clinical trials surrounding the medication Retatrutide , specifically the 120 milligram formulation referred to as ZPHC, indicate a considerable benefit on body mass loss and associated chronic conditions . Researchers believe that this dual agonist , affecting both GLP-1 and GIP pathways , could provide a major advance in the approach of ov